Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

3270 - Treatment Pattern and Clinical Outcomes of Patients With Locally Advanced and Metastatic Melanoma in a Real-World Setting in China


21 Oct 2018


Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology



Tumour Site



Chuanliang Cui


Annals of Oncology (2018) 29 (suppl_8): viii442-viii466. 10.1093/annonc/mdy289


C. Cui1, X. Yan2, S. Liu3, A. Deitz4, L. Si5, Z. Chi2, X. Sheng6, B. Lian1, J. Li3, J. Ge3, X. Wang2, L. Mao6, B. Tang6, L. Zhou2, X. Bai6, S. Li2, B. Li3, H. Wu3, J. Guo6

Author affiliations

  • 1 Urology And Melanoma, Beijing Cancer Hospital, 100142 - Beijing/CN
  • 2 Urology And Melanoma, Beijing Cancer Hospital, Beijing/CN
  • 3 Medical Oncology, MSD China, Beijing/CN
  • 4 Medical Oncology, Merck & Co., Inc., Kenilworth/US
  • 5 Department Of Renal Cancer And Melanoma, Peking University Cancer Hospital-Beijing Cancer Hospital, 100142 - Beijing/CN
  • 6 Urology And Melanoma, Beijing Cancer Hospital, 100000 - Beijing/CN


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3270


In China, treatment options for late-stage melanoma, particularly for second-line (2L) therapy, are limited. This retrospective, observational study used electronic medical records (EMRs) of patients (pts) with melanoma treated at Beijing Cancer Hospital (BCH) to describe the treatment pattern and real-world clinical outcomes in locally advanced, metastatic melanoma in China.


All adult pts with unresectable stage III or IV melanoma who initiated treatment between Jan 1, 2014, and Dec 31, 2015, were eligible. Pts were treated and followed up with regular imaging (every 3 mo). Trained researchers performed additional medical chart reviews to supplement data captured in the EMR database. Complete or partial responses, per RECIST v1.1 were adjudicated case by case. Survival analysis involved the Kaplan-Meier method, pts were censored at last known date alive before Dec 31, 2017.


Of 248 pts included in the study, 40.7% and 30.6% had acral and mucosal histology, respectively; almost all (∼95%) had stage IV melanoma; 221 received first-line (1L) therapy and 116 received 2L therapy (89 received both at BCH within the treatment period). The most common 1L regimens were dacarbazine + cisplatin + recombinant human endostatin (RHE) (36.7%) and paclitaxel + carboplatin + bevacizumab (22.2%). The most common 2L regimens were paclitaxel albumin + carboplatin + bevacizumab (22.4%), paclitaxel + carboplatin + RHE (15.5%) and paclitaxel albumin + cisplatin + RHE (12.1%). Clinical outcomes in pts with advanced melanoma are summarized in the table and are generally unfavorable: ORR <10%; median PFS <4 months; median OS < 1 year. Median DOR was 9.1 mo for 1L and 7.5 mo for 2L therapy.Table: 1283P

1L Therapy (N = 221)2L Therapy (N = 116)
CR, n20
PR, n124
ORR, % (95% CI)6.3% (3.5-10.4)3.4% (0.9-8.6)
Median DOR (range), months9.1 (1.7-28.4+)7.5 (4.6-24.2+)
Median PFS (95% CI), months3.5 (2.9-4.2)2.3 (2.0-3.0)
12-month PFS rate10.6%5.2%
Deaths, n (%)171 (77.4)101 (87.1)
Median OS (95% CI), months10.5 (9.2-12.1)7.5 (6.5-8.7)
12-month OS rate43.5%30.5%

CI, confidence interval; CR, complete response; DOR, duration of response; 1L, first-line therapy; 2L, second-line therapy; ORR, objective response rate; OS, overall survival; PR, partial response; PFS, progression-free survival.


The poor outcomes observed in this study suggest a high degree of unmet medical need for advanced melanoma in China in both the 1L and 2L settings.

Clinical trial identification

Legal entity responsible for the study

Merck & Co., Inc.


Merck & Co., Inc.

Editorial Acknowledgement

Medical writing and/or editorial assistance was provided by Doyel Mitra, PhD, of the ApotheCom pembrolizumab team, Yardley, PA, USA. This assistance was funded by Merck & Co., Inc., Kenilworth, NJ, USA.


C. Cui, X. Yan, L. Si, Z. Chi, X. Sheng, X. Wang, L. Mao, B. Tang, L. Zhou, X. Bai, S. Li: Research funding: Merck & Co., Inc. S. Liu, J. Li, J. Ge, H. Wu: Employee, Stockholder: MSD China. A. Deitz: Employee, Stockholder: Merck & Co., Inc. B. Lian: Research funding: Merck. B. Li: Employee: MSD China. J. Guo: Research funding, Advisory board: Merck & Co., Inc.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.